跳至主要内容
临床试验/NCT00224952
NCT00224952已完成不适用

The Role of Drug Metabolizing Enzymes in the Pathogenesis Adverse Drug Reactions in Children

Children's Mercy Hospital Kansas City3 个研究点 分布在 1 个国家目标入组 274 人开始时间: 2002年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
274
试验地点
3
主要终点
Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine

研究概览

简要总结

The purpose of the study is to examine the individual metabolic profiles of pediatric patients receiving carbamazepine or valproate therapy, in an attempt to determine identities of the reactive metabolites or, alternatively, the identities of those metabolites that serve as potential precursors to reactive species.

详细描述

Adverse drug reactions can be broadly defined as any undesirable response associated with therapeutic drug use. A simple and clinically useful classification is to divide adverse events into those that are dose-dependent and largely predictable from the known pharmacologic properties of the compound in question, and those that are dependent on characteristics unique to susceptible individuals, or idiosyncratic in nature.

The long term objective of this research is to characterize the mechanisms responsible for the pathogenesis of idiosyncratic hypersensitivity reactions in children, particularly those involving carbamazepine and other aromatic anticonvulsants.

The study is divided into two phases. Phase 1 of the study involves collecting urine from 50 patients taking CBZ therapeutically. Participants will be asked to provide a spot urine sample during routine health visits. The urine will be analyzed for the presence of CBZ and its metabolites. In Phase 2 of the study, urine will be collected from patients taking either CBZ or VPA therapeutically. If blood samples are drawn from these patients for medical purposes not related to this study the residual blood sample will be recovered before it is discarded for use in genotyping analysis. Participants will be asked to provide a urine sample covering one complete dosing interval of CBZ or VPA (preferably overnight). Patients will also be followed longitudinally, with urine collections at each clinic visit over at least a two year period.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
1 Year 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Pediatric patients of both genders between 1 and 16 years of age receiving CBZ or VPA mono-therapy will be recruited for this study. Additionally, for those patients who are receiving drugs other than CBZ or VPA to control their seizures, if CBZ or VPA are subsequently added to their treatment regimen, then these patients will also be recruited for this study.

排除标准

  • 未提供

结局指标

主要结局

Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine

时间窗: urine samples (overnight collections) collected longitudinally through study completion for time frame ranging from 2-5 years

1. To examine the individual metabolic profiles of pediatric patients receiving carbamazepine or valproate therapy, in an attempt to determine the identities of the reactive metabolites or, alternatively, the identities of those metabolites that serve as potential precursors to reactive species (e.g., through conjugation with detoxifying compounds such as glutathione).

次要结局

  • Age-related Changes in Bioactivation(urine samples (overnight collections) collected longitudinally through study completion for time frame ranging from 2-5 years)

研究者

发起方
Children's Mercy Hospital Kansas City
申办方类型
Other
责任方
Principal Investigator
主要研究者

Steve Leeder

Pharm.D; Ph.D

Children's Mercy Hospital Kansas City

研究点 (3)

Loading locations...

相似试验

Pathogenesis of Adverse Drug Reactions | 临床试验